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Abstract
In an analysis of 31,717 cancer cases and 26,136 cancer-free controls drawn from 13 genome-wide
association studies (GWAS), we observed large chromosomal abnormalities in a subset of clones
from DNA obtained from blood or buccal samples. Mosaic chromosomal abnormalities, either
aneuploidy or copy-neutral loss of heterozygosity, of size >2 Mb were observed in autosomes of
517 individuals (0.89%) with abnormal cell proportions between 7% and 95%. In cancer-free
individuals, the frequency increased with age; 0.23% under 50 and 1.91% between 75 and 79
(p=4.8×10−8). Mosaic abnormalities were more frequent in individuals with solid-tumors (0.97%
versus 0.74% in cancer-free individuals, OR=1.25, p=0.016), with a stronger association for cases
who had DNA collected prior to diagnosis or treatment (OR=1.45, p=0.0005). Detectable clonal
mosaicism was common in individuals for whom DNA was collected at least one year prior to
diagnosis of leukemia compared to cancer-free individuals (OR=35.4, p=3.8×10−11). These
findings underscore the importance of the role and time-dependent nature of somatic events in the
etiology of cancer and other late-onset diseases.
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Classically, genetic mosaicism is defined as the co-existence of cells with two or more
distinct karyotypes within an individual that results from a post-zygotic event during
development and can occur in both somatic and germline cells1,2. Errors in chromosomal
duplication and subsequent transmission to daughter cells may lead to aneuploidy, the gain
or loss of chromosomes or segments of chromosomes, and reciprocal gain and loss events
manifesting in copy-neutral loss of heterozygosity (cnloh) or acquired uniparental disomy.
Somatic mosaicism has been established as a cause of miscarriage, birth defects,
developmental delay, and cancer3-9. Because mosaicism can be benign or may manifest with
diverse clinical phenotypes, there are no accurate estimates of its frequency in the general
population3,6. On rare occasions the propensity to develop chromosomal abnormalities is
inherited and leads to multiple phenotypic abnormalities including cancer predisposition as
reported in families with mutations in BUB1B and CEP57 10,11. Recently, two groups have
identified somatic mosaic mutations in IDH1 and IDH2 in tumors of individuals with Ollier
disease and Maffucci syndrome12,13 while another group has characterized somatic
mosaicism of a HRAS mutation in an individual with urothelial cancer and epidermal
nevus14. Recent work in a population of twins has suggested that the detection of somatic
structural variants in blood increases with aging and may be related to reduction in blood
cell clonality15. In this report, we define mosaic chromosomal abnormalities broadly: the
presence of both normal karyotypes and those with large structural genomic events resulting
in alteration of copy number or loss of heterozygosity in distinct and detectable
subpopulations of cells regardless of the clonal or developmental origin of the
subpopulations.
Recently, we reported on 1,991 individuals from the Spanish Bladder Cancer/EPICURO
population-based case-control study in which we had performed a GWAS of adult-onset
bladder cancer using DNA obtained from blood or buccal samples16. The SNP array data
generated for the GWAS was subsequently used to detect clonal mosaic abnormalities in the
autosomes of 1.7% of study subjects, suggesting a higher frequency in adults than
previously suspected. Even though somatic mosaicism has been implicated in several
cancers, this study did not reveal a significant difference in frequency between cases and
controls. A computational algorithm was used to detect 42 large mosaic events involving
two or more distinct clones in DNA extracted from blood or buccal samples and we
experimentally validated the findings using multiplex ligation-dependent probe
amplification (MLPA) and microsatellite analysis (as well as fluorescent in situ
hybridization in a subset), establishing the robustness of the software detection method. A
similar proportion of cells carrying each event was found in 5 of 6 events (in four
individuals with bladder cancer in whom three had one event and one individual with three
separate events) in which it was possible to examine more than one tissue (whole blood and
bladder mucosa), suggesting an early embryonic origin of the somatic mutation leading to
the observed mosaic chromosomal abnormalities16.
Results
In this report, we extend our analysis of clonal mosaic abnormalities in the autosomes to
57,853 individuals (including those previously published16). We tested 31,717 cancer cases
and 26,136 cancer free controls for evidence of mosaic abnormalities using genome-wide
SNP array data generated as part of 13 distinct cancer GWAS drawn from 48
epidemiological case-control and case-cohort studies (Supplementary Table 1). DNA
samples were extracted from blood or buccal samples using a variety of collection and
extraction techniques and genotyped using one or more Infinium Human SNP arrays from
Illumina Inc. (including versions of Hap300, Hap240, Hap550, Hap610, Hap660, Hap1,
Omni Express, and Omni1). Genotype clusters were empirically estimated in 45 batches to
optimize accuracy while minimizing potential batch effects (Online Methods).
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Detection of clonal mosaic events was based on assessment of allelic imbalance and copy
number changes. We used the B-allele frequency (BAF) measurement, derived from the
ratio of probe values relative to the locations of the estimated genotype-specific clusters, for
initial segmentation using the Mosaic Alteration Detection (MAD) algorithm implemented
in GADA-R with modifications17,18. The BAF and log2 relative probe intensity ratio (LRR),
which provides data on copy number, were used to classify each event as copy-altering (gain
or loss) or neutral (reciprocal gain and loss resulting in loss of heterozygosity, LOH) and to
assign the proportions of abnormal (p) and normal (1-p) cells. Mosaic proportions were
required to deviate from levels expected from constitutional (non-mosaic) changes in order
to exclude homozygous chromosomal segments inherited identical by descent and non-
mosaic instances of trisomy, monosomy and uniparental disomy. A minimum event size
threshold was set to detect only clonal mosaic events greater than 2 Mbps to minimize the
false discovery of constitutional copy number variants. Copy-neutral LOH and copy-loss
events could be detected for mosaic proportions between 7% and 95% (Figure 1) with
sensitivity that was affected by the signal-to-noise ratio characteristic of each microarray
assay and sample quality. There was reduced sensitivity to distinguish between copy-neutral
LOH and copy-loss events for mosaic proportions less than 15% across the autosomes. The
magnitude of BAF differences for single-copy gain events was 1/3 of the magnitude of
copy-neutral LOH or copy-loss events, reducing the sensitivity for calling copy-gain events.
As a result, single copy gain events could only be reliably detected for mosaic proportions
between 22% and 88%, with ambiguity in distinguishing copy-gain from copy-neutral LOH
for mosaic proportions of less than 20%. Since DNA was obtained for the purpose of
performing a GWAS, it was not possible to further explore the developmental and clonal
characteristics of mosaic events detected in these individuals (e.g. by studying DNA from
fractionated blood and other tissue types, determining cell composition of buccal samples, or
effect of DNA collection and extraction methods on detection and accuracy of the estimation
of mosaic proportions). We report only autosomal chromosomal abnormalities, as the
analysis of the sex chromosomes presents distinct technical and interpretative challenges.
We observed 681 mosaic segments of size greater than 2 Mb on 641 autosomal
chromosomes in 517 individuals for an overall frequency of individuals with mosaicism of
0.87% (Tables 1 and 2). The most frequent type of event observed was copy-neutral LOH
(48.2%), while copy-gains and copy-losses were observed for 15.1% and 34.8% of mosaic
events, respectively (Table 1). A small proportion (1.9%) of mosaic chromosomes were
complex, harboring more than one type of event. 18.7% of mosaic chromosomal events
spanned the entire chromosome, including 62 complete trisomies, predominantly in
chromosomes 8, 12 and 15. 47.9% of mosaic chromosomal events began at a telomere and
extended across some portion of the chromosomal arm (Table 1 and Figure 2). The majority
of telomeric events were mosaic copy-neutral LOH (85.7%), most frequently on 9p (Table
3). The remaining mosaic chromosomal events were interstitial (31.5%) spanning neither
telomere nor centromere, while an additional small proportion (1.8%) spanned the
centromere or had more complex structure (e.g. distinct events involving both telomeres, but
not the whole chromosome). The majority of interstitial events were mosaic copy-loss
(91.6%), which was most frequently observed within specific regions of chromosomes 13q
and 20q (Figure 2). We observed 69 individuals (46 cancer cases and 23 cancer-free
individuals) with clonal mosaic events on multiple chromosomes. The distribution of the
number of clonal mosaic chromosomal events per individual is shown in Supplementary
Table 3. Among cancer-free individuals, the greatest number observed was 5 mosaic
chromosomal events, whereas six individuals with cancer had greater than 5 events,
including two individuals with gastric cancer who each had 20. A list of mosaic events with
phenotype data is available as Supplementary Data.
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The strongest predictor of mosaic autosomal abnormalities was age at DNA collection. We
examined the effect of aging on the frequency of mosaicism across all studies, which were
predominantly individuals over the age of 50. The frequency of cancer-free individuals with
detectable clonal mosaic events increased with age, from 0.23% for those under 50 to 1.91%
(p=4.8×10−8) for those between the ages of 75 and 79, and with slightly higher frequencies
for individuals with cancer (Figure 3). In the early onset cancers (under age 40), which
constituted less than 5% of analyzed cases (e.g., testicular cancer and osteogenic sarcoma),
we did not observe an increase in mosaic abnormalities. Further studies are needed to
investigate the relationship between mosaic abnormalities and cancer in children and young
adults, particularly because of the strong association between mosaicism and many
developmental disorders. There was no apparent relationship between age at DNA collection
and the number, size of mosaic events, or the proportion of abnormal cells (Supplementary
Figures 1 and 2).
We regressed the presence of detectable clonal mosaicism in 26,136 cancer-free individuals
on age at DNA collection (in 5 year intervals), sex (male versus female), DNA source
(buccal cells versus blood), smoking (ever versus never) and admixture coefficients for
African and East Asian ancestry in a logistic model to determine the additional factors that
influenced frequency of detectable clonal mosaicism. The source of DNA was known for
87% of individuals, of whom 19% were derived from buccal cells and the remainder from
blood. DNA source was not significantly associated with mosaicism (OR=0.83, 0.55-1.26
95% confidence interval (CI), p=0.39). By admixture analysis, 75% of subjects were
determined to be of European ancestry, 9% of African ancestry and 16% of East Asian
ancestry. Although power was limited, we observed that cancer-free individuals with
African admixture were at a lower risk of being mosaic (OR=0.43, 0.20-0.92 95% CI,
p=0.03), but not in those with East Asian admixture (OR=0.60, 0.32-1.15 95% CI, p=0.12).
We did not observe an association between smoking (ever/never) and frequency of mosaic
abnormalities (OR=1.04, 0.75-1.44 95% CI, p=0.81).
In 26,136 cancer-free controls and 23,093 cancer cases drawn from non-sex specific and
non-hematological cancer sites (i.e. excluding 8,470 individuals with leukemia, lymphoma,
multiple myeloma and cancers of the breast, endometrium, ovary, testis, and prostate), we
observed a higher frequency of males with mosaic abnormalities than females. In cancer-
free individuals, we observed mosaic events in 0.56% of females and 0.87% males
(OR=1.35, 0.98-1.88 95% CI, p=0.07); for individuals with cancer we observed mosaic
events in 0.79% of females and 1.21% of males (OR=1.48, 1.08-2.03 95% CI, p=0.015); and
overall, 0.65% of females and 1.04% of males (OR=1.42, 1.14-1.80 95% CI, p=0.002) in
logistic models adjusted for cancer diagnosis (if applicable), age at DNA collection,
ancestry, DNA source and smoking. These differences could be due to a true sex-specific
effect akin to sex-differential mutation and recombination rates19; however the complex and
heterogeneous nature of the inclusion of individual studies and the differences in their entry
and selection criteria could result in spurious associations. Although this observation was
consistent across cancer types, it should be confirmed in additional studies better designed to
address this question.
To determine the relationship between detectable mosaic autosomal abnormalities and non-
hematological cancers, we regressed the presence of detectable clonal mosaicism on cancer
diagnosis, age, sex, DNA source, smoking and ancestry in a logistic model. We observed a
modest increase in cancer risk for mosaic individuals (OR=1.27, 1.05-1.52 95% CI,
p=0.012) (Tables 2 & Supplementary Table 2). Notable associations were observed in
stratified analyses of lung (OR=1.56, 1.18-2.08 95% CI, p=0.002) and kidney (OR=1.98,
1.27-3.06 95% CI, p=0.002) cancers, both tobacco-associated malignancies. However no
cancer site-specific associations were observed for bladder, esophagus, stomach and
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pancreas cancers, which are also typically associated with tobacco use. There was no
significant association in non-hematological cancer cases overall between smoking (ever/
never) and frequency of mosaicism (OR=1.19, 0.92-1.54 95% CI, p=0.19) or when stratified
by cancer site (results not shown).
In an analysis of the subset of 14,050 individuals with cancer for whom it was possible to
determine that DNA was likely obtained before or at the time of diagnosis and prior to
treatment with radiation or chemotherapy for a primary tumor (designated as “likely
untreated”), we observed a stronger association between mosaic abnormalities and non-
hematological cancer diagnosis (OR=1.45, 1.18-1.80 95% CI, p=0.0005). The associations
for lung and kidney also increased in significance (Table 3). It is notable that the evidence
for association with non-hematological cancer diminished in individuals who were
potentially treated (OR=1.03, 0.81-1.30 95% CI, p=0.80). We had approached this analysis
with the hypothesis that there could be an increased frequency in detectable clonal
mosaicism in non-hematological cancers induced by chemotherapy or radiotherapy but were
surprised to observe the frequency was reduced to virtually the same as in the cancer-free
population. Although this attenuated effect could have many explanations (e.g., related to
the diagnosis and treatment of a solid tumor leading to a decrease in populations of cells
with mosaic alteration), we had a limited capacity to model and control for treatment-effects
since many of the studies did not provide any treatment information or only provided
incomplete, retrospective ascertainment of the specifics. Although many of the participating
studies were prospectively ascertained cohorts, DNA collection often occurred after cancer
diagnosis. Additional studies are needed in prospectively ascertained cohorts and
longitudinal studies in which multiple DNA samples were collected prior to and after
diagnosis in order to explore treatment and disease effects.
For the 43 individuals with hematological cancers for whom DNA was obtained at least a
year prior to diagnosis, the frequency of detectable clonal mosaicism was 20% for myeloid
leukemia and 22% for lymphocytic leukemia (predominantly chronic lymphocytic leukemia,
Table 2) compared to 0.74% in 26,136 cancer free controls (overall OR=35.4, 14.7-76.6
95% CI, Fisher exact p=3.8×10−11). Of the 8 mosaic individuals with leukemia for whom
DNA samples were collected at least a year prior to diagnosis, 4 were diagnosed with
chronic lymphocytic leukemia (CLL) of which 2 had a mosaic deletion in a region of
chromosome 13q14 previously described to be deleted in CLL20. DNA was obtained more
than 5 years prior to diagnosis for 6 mosaic individuals, with the longest interval being 14
years, suggesting that detectable clonal mosaicism could be a marker of hematological
cancer or its precursors, i.e., monoclonal B cell lymphocytosis (MBL) for CLL and
myelodysplastic syndrome for acute myelogenous leukemia. Recent work shows that the
majority of MBL have mono- or biallelic 13q14 abnormalities21. However, further studies
will be needed, preferably with serial pre- and post- diagnosis sampling to investigate the
predictive nature of detectable clonal mosaicism, especially involving regions of
chromosome 13 and 20 with respect to leukemia risk20.
We further explored the 4 most recurrent altered regions (>20), which also harbor well
known cancer genes (as noted in the COSMIC22 and Mitelman databases: http://
cgap.nci.nih.gov/Chromosomes/Mitelman); these were on chromosomes 9p (cnloh), 13q
(del), 14 (cnloh) and 20q (del) (Table 4). Notably, the most recurrent mosaic events were
observed in cancer-free individuals as well as across multiple solid tumors. We observed a
comparable frequency in non-hematologic cancer cases and cancer-free controls for three of
the regions, whereas the chromosome 14 cnloh abnormalities were more frequent in non-
hematological cancer cases (OR=3.32, 1.42-9.00 95% CI, Fisher’s exact p=0.003),
particularly in individuals with bladder or kidney cancer. Copy-neutral loh in this region of
chromosome 14 has been associated with increased susceptibility to sporadic cancers and
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harbors imprinted genes, such as the tumor suppressing non-coding RNA, Maternally
expressed gene 3 (MEG3)8,23. The recurrent segmental deletion of 13q14 was observed in 5
leukemia cases, but also in 18 individuals with solid tumors (9 with lung cancer and 4 with
prostate cancer), and in 10 cancer-free individuals. This region includes the tumor
suppressor gene DLEU7 (Deleted In Leukemia 7) and related genes, DLEU1 and DLEU2,
the latter harboring two microRNAs within one of its introns (miR-15a and miR-16-1)24-26.
The retinoblastoma gene, RB1 was also included within a subset harboring a mosaic
deletion of 13q14. It cannot be ruled out that these individuals have either undiagnosed CLL
or MBL. The 20q- was seen in two individuals with myeloid leukemia as has been described
previously27 but also in cancer-free and individuals with solid tumors.
The accuracy of our software methods to detect clonal mosaic abnormalities was previously
addressed and we were able to validate 100% of 42 events in 34 individuals from the
Spanish Bladder Cancer Study using confirmatory cytogenetic assays16 (Supplementary
Figure 3). We have also performed a comparison of mosaic events in samples from the
EAGLE and PLCO lung cancer studies which were independently analyzed as part of the
Gene, Environment Association studies consortium (GENEVA) report on mosaic events28.
A total of 83 mosaic events in individuals from the EAGLE and PLCO lung cancer studies
were detected in common, 20 additional events of size less than 2 Mb and 8 events greater
than 2 Mb were detected by GENEVA and not by our study, while we detected 20 additional
events (size > 2 Mb) that were not detected by GENEVA. Although additional cytogenetic
or molecular validation was not performed, neither method detected notable false-positive
events based on manual review of the data. The concordance rate is 75% if considering
events > 2 Mb (the cut-off for this analysis) or 63% if considering all events, both of which
are considerably better than the 25-50% concordance rates observed across CNV detection
methods29-31. Our method is more conservative in the size of events detected, while the
GENEVA method is more conservative with respect to sample quality, but provides calls for
smaller events when assay quality is sufficient. Better approaches are needed to characterize
smaller size events accurately as either mosaic or constitutional and to estimate their
frequency. Further improvements to data normalization, segmentation and event
classification methods will also likely reduce false-negative rates.
Discussion
Our study has important implications for the design and analysis of molecular epidemiology
studies in cancer as well as the somatic characterization of cancer genomes, like The Cancer
Genome Atlas32 and International Cancer Genome Consortium33. Investigators will need to
carefully analyze samples used as exemplars of germline DNA for somatic alterations, such
as detectable clonal mosaicism. Otherwise, comparisons between “grmline” and tumor DNA
may result in implausible somatic changes (e.g. large gains of heterozygosity) and it may be
impossible to determine whether somatic events pre-date changes secondary to driver
mutations. Since how to detect mosaic events with next generation sequencing technologies
is neither routine nor well understood, for the near future it may be prudent to continue to
utilize SNP microarrays for such analyses. Due to the increased frequency of detectable
clonal mosaicism with age, this will be particularly important for the analysis of epithelial
cancers, which characteristically occur in the older population. For future large-scale GWAS
in prospective studies, it may be wise to consider analyzing the earliest, pre-diagnosis DNA
samples and to consider time from collection to diagnosis in the analysis of longitudinally
collected biospecimens.
We have extended our initial observation that detectable clonal mosaicism of the autosomes
is present in the population with surprising frequency and particularly in the aging genome.
A recent study of detectable clonal mosaicism in twins reported an increase in frequency
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with age and suggested that this reduction could lead to a less diverse blood cell population
and immune system15. These emerging data raise a number of critical issues in mechanisms
underlying the possible shift in the repertoire of clones with large structural abnormalities.
Thus cells with abnormal karyotypes could have an early developmental origin in which a
somatic event in a single stem cell progenitor during embryogenesis could become apparent
when cellular diversity decreases with age and cell populations become increasingly
oligoclonal. Higher rates of detectable clonal mosaicism in older cancer-free individuals
could also be due to increased rates of somatic mutation or diminished capacity for genomic
maintenance, such as with telomere attrition34 leading to proliferation of somatically altered
cell populations. A survival bottleneck of cellular progenitors could also lead to observable
mosaic alterations that were previously below the threshold of detection but subsequently
expanded due to positive selection. Further work is required to begin to unravel the
underlying mechanisms that result in mosaic abnormalities, particularly as it relates to how
and when altered clones are created, tissue-specificity, and the timing and expansion of
distinct populations of cells with age. Finally, these findings underscore the importance of
considering the role and time-dependent nature of somatic events in the etiology of cancer as
well as other late-onset diseases.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Characteristics of detectable clonal mosaic events
Detectable clonal mosaic events plotted by proportion of abnormal cells (p) and Log R Ratio
(LRR) for 681 events in 517 individuals.
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Figure 2. Circular genomic plot of detectable clonal mosaic events
Genomic location of detectable clonal mosaic events. Outer rings are the autosomes 1 to 22.
Yellow region denotes events of copy neutral loss of heterozygosity. Blue region denotes
copy gain events. Red region denotes copy loss events. Panel A includes events in cancer
free controls. Panel B includes events in cancer cases.
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Figure 3. Frequency of detectable clonal mosaic events by age and cancer status
Analysis excluded 1,000 individuals with unknown age at DNA collection. 95% confidence
intervals are shown.
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